Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma
In this study, safety and effects of IPM001 vaccine on human hepatocellular carcinoma are going to be investigated, IPM001 is a neoantigen/tumor-specific antigen sensitized autoimmune cell injection
Hepatocellular Carcinoma
BIOLOGICAL: IPM001
DFS, The time between the NeoAg/aeTSA CTL initiation and the onset of tumor recurrence or death from any cause, 18 months
OS, From the beginning of NeoAg/aeTSA CTL initiation to the time of death from any cause, 24 months|EORTC-QLQ30, 18 months
In this study, safety and effects of IPM001 vaccine on human hepatocellular carcinoma are going to be investigated, IPM001 is a neoantigen/tumor-specific antigen sensitized autoimmune cell injection